dm+d

327397006

Articles

Trastuzumab: informing intrathecal risk assessment

11 August 2022Trastuzumab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Search Articles

Refrigerated Storage

HerceptinRoche Products Ltd

Roche Products Ltd
Herceptin
600mg solution for injection in vial

In the event of an inadvertent temperature excursion the following data may be used:
Once removed from the refrigerator Herceptin subcutaneous formulation must be administered within 6 hours and should not be kept above 30°C.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

12 October 2022
London MI Service

Herceptin Roche Products Ltd

Roche Products Ltd
Herceptin
150mg powder for concentrate for solution for infusion

Contact Roche Products Limited in all cases where a deviation from the recommended storage conditions has occurred. Refer to the electronic medicines compendium (eMC) at https://www.medicines.org.uk for company contact details.

12 October 2022
London MI Service

Herzuma Napp Pharmaceuticals

Napp Pharmaceuticals
Herzuma
Powder for concentrate for solution for infusion, 150mg and 420mg

In the event of an inadvertent temperature excursion the following data may be used:
In-house stability data shows Herzuma 150mg was stable for 36 months and Herzuma 420mg was stable for 12 months at storage conditions (2°C to 8°C) when exposed to stress/cycling stability conditions (a total of 12 days at temperatures cycling between -20 ± 5°C and 40 ± 2°C).

In-house stability data from the manufacturers have shown that the unopened vials may be kept up to 25°C for 6 months, or up to 40°C for 3 months.

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

28 January 2022
London MI Service

Lactation Safety Information

No
No published evidence of safety
Serious adverse effects reported in adults
Low levels anticipated in milk due to the drug’s properties and likely to be degraded in infant’s GI tract. However, the effects on the infant of even small amounts in breast milk are unknown
16 September 2020